Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Cardiome closes C$30 million primary and secondary common share offering

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Confidential Clients

On March 11, 2014, Cardiome Pharma Corp. (“Cardiome”) and CarCor Investment Holdings LLC (“CarCor”), the shareholder from which Cardiome purchased Correvio LLC, completed a prospectus offering of 1,500,000 common shares from treasury of Cardiome for gross proceeds of C$15 million and 1,500,000 common shares in a secondary offering from CarCor for gross proceeds of C$15 million, both at C$10.00 per common share, for aggregate gross proceeds of C$30 million. The offering was made on a bought deal basis through a syndicate of underwriters with Canaccord Genuity Corp., acting as sole bookrunner and co-lead underwriter, and Cormark Securities Inc., acting as co-lead underwriter. The underwriters were advised by a team of Fasken Martineau lawyers that included Rubin Rapuch, Brad Freelan, Jessica Catton, Aidan Hyde (Capital Markets) and Mark Penner (Intellectual Property).

Team

    Subscribe

    Receive email updates from our team

    Subscribe